Furthermore, we speculate that D2R agonist treatment may reduce immunosuppression within the tumour microenvironment, based upon our prior studies demonstrating that D2R agonist treatment reduces tumour-infiltrating myeloid-derived suppressor cells in NSCLC [60]. The gene discussed is DRD2; the disease is non-small cell lung carcinoma.